Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 77.35M P/E - EPS this Y 22.00% Ern Qtrly Grth -
Income -86.76M Forward P/E -1.00 EPS next Y 13.70% 50D Avg Chg -5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -29.00%
Dividend N/A Price/Book 0.62 EPS next 5Y - 52W High Chg -93.00%
Recommedations 2.00 Quick Ratio 7.39 Shares Outstanding 30.17M 52W Low Chg 42.00%
Insider Own 8.04% ROA -59.13% Shares Float 27.53M Beta 0.51
Inst Own 46.17% ROE -100.41% Shares Shorted/Prior 1.18M/1.29M Price 2.57
Gross Margin - Profit Margin - Avg. Volume 187,843 Target Price 12.50
Oper. Margin - Earnings Date Nov 6 Volume 89,237 Change 0.39%
About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Relmada Therapeutics, Inc. News
11/19/24 Relmada Therapeutics to Present at Jefferies London Healthcare Conference
11/14/24 Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
11/10/24 Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024
11/08/24 Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ...
11/07/24 Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/04/24 Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
10/22/24 3 US Penny Stocks To Monitor In October 2024
09/13/24 Insider Spends US$395k Buying More Shares In Relmada Therapeutics
09/12/24 Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD)
09/12/24 Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares
05:22 AM Will Relmada Therapeutics (NASDAQ:RLMD) Spend Its Cash Wisely?
08/12/24 Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
08/08/24 Q2 2024 Relmada Therapeutics Inc Earnings Call
08/07/24 Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
07/11/24 Institutional investors have a lot riding on Relmada Therapeutics, Inc. (NASDAQ:RLMD) with 48% ownership
06/18/24 Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
06/10/24 Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
06/03/24 Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
05/28/24 7 Penny Biotech Stocks to Triple Your Investment
05/11/24 Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript
RLMD Chatroom

User Image NVDAMillionaire Posted - 2 hours ago

$RLMD Relmada Therapeutics (RLMD): Navigating the Complexities of CNS Drug Development https://beyondspx.com/article/relmada-therapeutics-rlmd-navigating-the-complexities-of-cns-drug-development

User Image RiskCPremium Posted - 19 hours ago

$RLMD Today, 11/20/2024, Sergio Traversa said that interim analysis data would be announced within 2, 3, or 4 weeks while attending in Jefferies London Healthcare Conf. Understandably, market is discounting it due to Management/BOD's unbounded incompetencies, consistently missing milestones, and bottomless greed and self-enrichment scheme. I do not know if the stock will rise at all with positive interim analysis data. I am afraid market will keep discounting it until there is hard top line results. Sergio stated that in Reliance-1 (301), post hoc analysis, Covid lockdown data - futile vs. after lockdown restriction lifted data - delta around ~= 6.0, Rel-1017 vs Placebo. If that is the case, I am not sure why is there not enough resource/push to complete the Reliance-II (302) and announce the TLR instead of taking months and spending limited cash for interim analysis? If RLMD misses Reliance-II(302), there will be nothing left of RLMD to feel any pain.

User Image VictorMason Posted - 1 day ago

$RLMD Don’t jump yet Jeffries still thinks it has a chance to hit $35 on a clean phase 3 Today in Rio Hondo: ‘no swimming’

User Image VictorMason Posted - 1 day ago

$RLMD getting close, just need HPK to get taken over first

User Image NevD Posted - 2 days ago

$RLMD Q? My buyin was $3.50 a few months ago, will RLMD hit $4.00 before Phase one ends ? And how long does Phase 1 take ?

User Image perchedcats Posted - 3 days ago

$RLMD finally they start p11 phase 1

User Image tvest Posted - 1 week ago

$RLMD

User Image fastpaymakesfastfriends Posted - 1 week ago

$RLMD peace piece! Good luck to all.

User Image philipv777 Posted - 1 week ago

$RLMD that 15min earnings call was disappointing. Timelines have slipped again. $is running low. No mention of cash lasting through to end of Rel2 trial anymore, just interim analysis. A capital raise early next year is almost guaranteed. I wonder how many they’ve enrolled in relight at this point because, as someone mentioned here, I suspect they are desperately trying to funnel all patients into rel 2 to get it to finish line before $ runs out. On the plus side, lower drop out rate than prior P3’s, which he said shouldn’t be read into but I will: it means that the likelihood of high quality patients enrolled with true MDD and positive effect of drug, is higher. Interim analysis is still huge derisking event/catalyst and I think they will have the data. So when diluted hopefully it will be at a higher valuation. Slow(disappointingly slow), but no reason to panic yet imo.

User Image d_risk Posted - 1 week ago

$RLMD - 10Q - Updated Risk Factors New risk factor: Doubt about RLMD's ability to continue as a going concern due to significant accumulated deficit and ongoing losses; uncertain success in securing additional funding. https://d-risk.ai/RLMD/10-Q/2024-11-07

User Image Gmebe Posted - 2 weeks ago

$RLMD rather a harsh sell off today. Earnings call is announced for the 7th Nov. Expect a nothing burger, regurgitating the same as before) imo unless they do a formal update before the trading day (in terms of p1 or p3 updates)

User Image VictorMason Posted - 2 weeks ago

$RLMD RLMD has enough cash ($70mm) to complete REL-1017 and begin P-1 the psilocybin weight loss project. Watch for them to spin off one or the other or sell the whole package to JNJ or LLY. $3billion+ ($100/ share)on a good phase 3 and or initial reports on P-1

User Image perchedcats Posted - 2 weeks ago

$RLMD when are they initiating obesity study? before EoY?

User Image VictorMason Posted - 10/28/24

$RLMD block of 125,000 shares @ $3.85 at 11:00:46 hmmm…

User Image VictorMason Posted - 10/25/24

$RLMD give me until HPK gets taken over, RLMD is a lead pipe cinch to hit $35 on news IAF gives 40 minute warning SOP, no civilians killed:

User Image NevD Posted - 10/23/24

$RLMD nice...

User Image Gmebe Posted - 10/23/24

$RLMD weird move by charles casamento. Buys 13k shares I. September at 2.56usd and then sells today with profit. The guy only ever seems to sell his shares once they're exercising and this appears to be his only open market buy that he's backed out of after a

User Image NevD Posted - 10/23/24

$RLMD bought his dip. 650 shares…. 🤞🏼 I need these results to be 👌 . Let’s get that $13 PT.

User Image NevD Posted - 10/22/24

I use another tool that displays the PreMarker gainers and losers. $GNPX was on top of the gainers today. I am not in it, but am in $RLMD for about 500 shares.

User Image NevD Posted - 10/22/24

$RLMD $SOFI … people , do you see the spiking $GNPX this morning? … that is exactly what is going to happen with $RLMD and more when positive results come, or even a sniff of positive results. But I would bet money so many penny flippers will bait at or before $4. I’ll see you at $10+, unless a buyout offer comes from the likes of Pfizer or another competitor…

User Image perchedcats Posted - 1 month ago

$RLMD 🤞🤞🤞results expected this Q

User Image NevD Posted - 1 month ago

$SOFI almost everything I have is red, except $SOFI and $RLMD. Speaks to Momentum and strength of these plays.

User Image NevD Posted - 1 month ago

$RLMD what's the chances this explodes past $4.50 ?

User Image VictorMason Posted - 1 month ago

$RLMD my Plan B in peril: RLMD getting hot before HPK goes out on a takeover,

User Image perchedcats Posted - 1 month ago

$DRUG interesting thing they will explore effects of their drug on obesity similar to $RLMD I guess issue for that is eventually raising money to broaden clinical programs

User Image NevD Posted - 1 month ago

$RLMD I need a win ... Christmas is coming...

User Image NevD Posted - 1 month ago

$RLMD in for 100 shares. Let’s go !!!

User Image VictorMason Posted - 1 month ago

$RLMD in the next 30-90(?) days RLMD will have at least two major announcements, If they fail the placebo arm again it’s $1, if they ran it correctly this time and the underlying data is as good as the last times it’s $35-$60, a great Vegas bet. I think the start of phase 1 on P-11 alone will get it to $10

User Image Qwikkzz Posted - 1 month ago

$RLMD Feels like $TOP a few days ago

User Image Qwikkzz Posted - 1 month ago

$RLMD Could it be this time? LOL

Analyst Ratings
Goldman Sachs Sell Jun 5, 24
Mizuho Buy Jun 15, 23
SVB Leerink Outperform Jan 23, 23
Goldman Sachs Neutral Oct 14, 22
Guggenheim Neutral Oct 14, 22
Oppenheimer Perform Oct 13, 22
Goldman Sachs Buy Sep 23, 22
Guggenheim Buy Sep 6, 22
Oppenheimer Outperform May 9, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
TRAVERSA SERGIO Chief Executive Offi.. Chief Executive Officer Jan 29 Buy 3.87 100,000 387,000 244,024 01/31/24
Shenouda Maged Chief Financial Offi.. Chief Financial Officer Jan 29 Buy 3.87 32,675 126,452 34,903 01/31/24
Ence Chuck CA and CO CA and CO Jan 29 Buy 3.86 38,970 150,424 38,970 01/31/24
TRAVERSA SERGIO Chief Executive Offi.. Chief Executive Officer Dec 08 Buy 2.096 55,250 115,804 144,024 12/12/22
Kelly Paul Edward Director Director Apr 04 Option 3.24 10,000 32,400 197,295 04/05/22
Kelly Paul Edward Director Director Apr 04 Sell 30.04 10,000 300,400 187,295 04/05/22
Shenouda Maged CFO CFO Mar 10 Option 3.24 10,000 32,400 12,228 03/10/21
Shenouda Maged CFO CFO Mar 10 Sell 35.39 10,000 353,900 2,228 03/10/21
TRAVERSA SERGIO CEO CEO Feb 16 Option 3.24 1,446 4,685 90,220 02/16/21
TRAVERSA SERGIO CEO CEO Feb 16 Sell 35.43 1,446 51,232 88,774 02/16/21
TRAVERSA SERGIO CEO CEO Feb 10 Option 3.24 11,206 36,307 99,980 02/10/21
TRAVERSA SERGIO CEO CEO Feb 10 Sell 35.17 11,206 394,115 88,774 02/10/21
Kelly Paul Edward Director Director Feb 10 Option 3.24 3,569 11,564 165,864 02/10/21
Kelly Paul Edward Director Director Feb 10 Sell 35.16 3,569 125,486 162,295 02/10/21
Shenouda Maged CFO CFO Feb 10 Sell 35.16 11,372 399,840 2,228 02/10/21
Shenouda Maged CFO CFO Feb 10 Option 3.24 11,372 36,845 13,600 02/10/21
TRAVERSA SERGIO CEO CEO Feb 04 Option 3.24 3,278 10,621 92,052 02/04/21
TRAVERSA SERGIO CEO CEO Feb 04 Sell 35.04 3,278 114,861 88,874 02/04/21
Shenouda Maged CFO CFO Feb 04 Option 3.24 3,200 10,368 5,428 02/04/21
Shenouda Maged CFO CFO Feb 04 Sell 35.02 3,200 112,064 2,228 02/04/21
TRAVERSA SERGIO CEO CEO Jan 29 Option 3.24 10,000 32,400 85,493 01/29/21
TRAVERSA SERGIO CEO CEO Jan 29 Sell 32.69 10,000 326,900 75,493 01/29/21
Kelly Paul Edward Director Director Jan 29 Option 3.24 5,000 16,200 152,295 01/29/21
Kelly Paul Edward Director Director Jan 29 Sell 32.66 5,000 163,300 147,295 01/29/21
Kelly Paul Edward Director Director Jan 26 Option 3.24 4,085 13,235 151,380 01/26/21
Kelly Paul Edward Director Director Jan 26 Sell 912.4 4,085 3,727,154 147,295 01/26/21
TRAVERSA SERGIO CEO CEO Jan 26 Option 3.24 4,070 13,187 79,563 01/26/21
TRAVERSA SERGIO CEO CEO Jan 26 Sell 35.51 4,070 144,526 75,493 01/26/21
Shenouda Maged CFO CFO Jan 26 Option 324 4,000 1,296,000 6,228 01/26/21
Shenouda Maged CFO CFO Jan 26 Sell 35.5 4,000 142,000 2,228 01/26/21
CASAMENTO CHARLES J Director Director Dec 02 Sell 35.74 3,000 107,220 24,950 12/02/20